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Tumor-derived extracellular vesicles have emerged as an alternative source of cancer biomarkers in liquid
biopsies. Despite their clinical potential, traditional methods for isolation and analysis have hampered their
translation into the clinic. The use of nanomaterial-based biosensors can speed up the development of
analytical methods for quantifying extracellular vesicles in a specific, highly reproducible, robust, fast and
inexpensive way. Here we review the utility of extracellular vesicles as a novel type of liquid biopsies and the
recent advances in nanoparticle-based biosensors for their analysis. We aim to emphasise the limitations and
challenges that hinder extracellular vesicle analysis using these biosensors and point out potential solutions.
1. Introduction
Liquid biopsies are considered a very promising alternative to
conventional tissue biopsies for cancer detection, monitoring
tumor progression and tracking tumor evolution.1 Recently,
tumor-derived extracellular vesicles (EVs) have emerged as an
alternative source of biomarkers in liquid biopsies. Although
EVs were initially proposed to be cellular waste, to date it is
known that they mediate intercellular communication and play
a major role in a variety of normal and pathological processes,
including cancer.2 As the cargoes that EVs carry largely depend
on their parent cells, EVs hold great promise as prognostic
elements.3 Despite their clinical potential, the use of complex
and time-consuming traditional methods for isolation and
analysis has limited their clinical translation.4 Furthermore,
characterization of EVs can be challenging because of the high
heterogeneity of the isolates, which generally contain a mix of
EVs of different origin, with diverse sizes and cargo content.5,6
In this context, the development of new analytical platforms to
perform high-throughput analyses in an easy and sensitive way
without sample pre-treatment could speed up their clinical
translation. Ideally, point of care (POC) biosensors will allow
for a sensitive, selective and fast detection of EVs while remaining
easy to use and inexpensive. In recent years great efforts have
been devoted to develop novel biosensors for EV analysis based
on microfluidics, nanomaterials or plasmonics to name a few.
However the majority of these platforms are only proof of concept
works that have not entered into the market.
In this review we present the recent progress in the detection
of EVs and describe the state-of-the-art in nanomaterial-based
biosensors. Although several reviews have focused on some
isolation and detection techniques,7–14 this review concentrates
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on the advantages of using nanomaterials, mainly nanoparticles
(NPs) to develop biosensors. We also provide a comprehensive
overview of the potential use of EVs as a novel type of liquid
biopsies and the techniques that are currently used to analyze EV
biomarkers in biofluids. Then, we focus on the advantages of
using NPs to design and develop innovative biosensors, and how
the correct selection of biomolecules and nanostructures and
the way to combine both could improve their analytical perfor-
mance. The main aim of this review is to present in a critical way
the state-of–the-art in NP-based biosensors and finally address
current challenges in the detection of EVs, considering the
advantages and limitations of each technique.
2. Liquid biopsies and extracellular
vesicles
2.1. Liquid biopsies
Liquid biopsies of cancer are samples of biofluids such as
blood or urine that are used for the analysis of cancer cells or
cancer tissue-derived molecules.15,16 Liquid biopsies have emerged
as a very promising alternative to conventional tissue biopsies
since they can be obtained in a noninvasive or minimally invasive
way, thus avoiding the risks related to tissue sampling and
allowing serial sampling during the course of disease. Importantly,
they have been shown to reflect intratumoral heterogeneity better
than tissue biopsies, and are suitable for longitudinal monitoring
of cancer evolution and detection of resistance-conferring tumor
cell subclones.17 Hence, liquid biopsies have a potential utility
for cancer diagnosis, detection of minimal residual disease,
tracking tumor progression and predicting the emergence of
chemoresistance.18 The most common types of liquid biopsies
are circulating tumor cells (CTCs) and circulating cell-free DNA
(cfDNA) or RNA (cfRNA) (Table 1).19–21 CTC analyses range from
the enumeration and immunophenotyping of CTCs to the single
cell genomic, transcriptomic or proteomic profiling and tumor
growth assays.19,22 cfDNA can be exploited for the detection and
quantification of tumor mutations, copy number variations and
methylation markers,21 whereas cfRNA can be used for the
profiling of mRNAs and non-coding RNAs, and the identification
Table 1 Main types of cancer liquid biopsies. The table shows the main liquid biopsies, and their main source and detection methods. The examples are
taken from ref. 25 except for some tumor-derived EV examples, where the readers are referred to ref. 26 and 27. Although many molecules have shown
their potential in liquid biopsies, there are still few of them that have reached the clinic and many need further validation
Types of liquid biopsies Main source Detection Example
Circulating
tumor cells
Cell count Blood Several approaches based
on the biological, physical and
functional properties of CTCs.
After CTC isolation, different
molecular analysis including NGS,
FISH and ICH or testing for drug
sensitivity can be done
Enumeration of CTCs by
CellSearch for metastatic breast,








Proteins Blood Immunoassays – PSA, prostate cancer
– CA 15–3, breast cancer
ctDNA: Any biofluid in
contact with cancer




translocations NGS – Epi proColon based on gene
methylation, colorectal cancermethylation
ctRNA: PCR (qPCR, dPCR) – hTERT, prostate cancer
– expression profiles
(i.e. of mRNAs, miRNAs,
lncRNAs)
– mRNA splicing RNA-Seq – PCA3, prostate cancer
Tumor-derived
EVs
EV count Any biofluid in
contact with cancer
Nanoparticle tracking analysis,
tunable resistive pulse sensing.
Other platforms are under
development
Increased in pancreatic cancer
Proteins: expression and
modifications
Mass spectrometry, ELISA Many examples such as Del-1 for
breast cancer
RNA: expression profiles,
i.e. of miRNA, lncRNA, mRNA
PCR, RNA-Seq Many examples such as
– AR-V7, prostate cancer
– ExoDx Prostate test




PCR, NGS Mutations in KRAS and TP53 in
pancreatic cancer





CA: cancer antigen; Ct: circulating tumor; CTC: circulating tumor cell; dPCR: digital PCR; FISH: fluorescence in situ hybridization; hTERT: human
telomerase reverse transcriptase; ICH: immunocytochemistry; NGS: next-generation sequencing; NSCLC: non-small cell lung cancer; lncRNA: long
noncoding RNA; PCA3: prostate cancer antigen 3; PSA: prostate-specific antigen; qPCR: quantitative PCR; RNA-Seq: RNA-sequencing
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of tumor-specific fusion transcripts and splice variants.22 Some
of such tests, for example the enumeration of CTCs using the
CELLSEARCHs CTC Test23 or the detection of epidermal growth
factor receptor (EGFR) mutations using the cobass EGFR Muta-
tion Test,24 have been approved by the Food and Drug Admin-
istration and are available for routine clinical use. More recently,
tumor-educated platelets and tumor-derived EVs have emerged
as an alternative source of cancer tissue-derived biomarkers in
liquid biopsies.18,22
2.2. Extracellular vesicles
The term ‘‘EV’’ refers to all types of particles released from cells
that are enclosed by a lipid bilayer and cannot replicate.28 EVs
contain a large variety of molecules, including proteins, nucleic
acids, lipids and metabolites. According to their biogenesis, three
main subtypes of EVs have been defined: exosomes, microvesicles
(also called ectosomes, shedding vesicles or microparticles) and
apoptotic bodies.29 Exosomes correspond to intraluminal vesicles
of multivesicular bodies that are released from cells after fusion of
the limiting membrane of these organelles with the plasma
membrane. The majority of them range between 30 and
150 nm in diameter.30,31 Microvesicles are generated by budding
from the plasma membrane and range between 50 and 1000 nm
in diameter.31 Apoptotic bodies are highly heterogeneous EVs
formed during apoptotic cell death, and the majority of them
have a diameter ranging between 1 and 5 mm. However, the
release of smaller EVs (o1 mm in diameter) during the progres-
sion of apoptosis has also been reported.32 Some specific types
of cancer cells have been found to release unusually large EVs
(1–10 mm in diameter) referred to as large oncosomes or large
EVs,33,34 but their biogenesis is not fully understood so far. As the
current methods for EV isolation do not allow accurate separation
of EV subtypes, the International Society for Extracellular Vesicles
(ISEV) in the recently updated position paper recommends using
the term ‘‘extracellular vesicle’’ instead of terms like ‘‘exosome’’ or
‘‘microvesicle’’, unless the biogenesis pathway of the studied
vesicles is clearly established.28 In this review, however, in order
to not modify the terminology of the revised manuscripts, we will
utilize the terms employed in the original works.
Although initially considered a waste disposal mechanism,35
both live cell and apoptotic cell-derived EVs have turned out to be
important mediators of intercellular communication acting in a
paracrine and systemic manner.32,36 Overwhelming evidence sug-
gests that cancer-derived EVs promote cancer progression in various
ways. For instance, EVs released by highly aggressive, drug resistant
or hypoxia-experienced cancer cells transfer their phenotypic traits to
other cancer cells.37–39 Cancer-derived EVs can also be taken up by
various cell types constituting the tumor microenvironment leading
to stromal activation, induction of angiogenesis, lymphangiogenesis
and immune suppression.40,41 Furthermore, cancer-derived EVs can
act systemically by helping to establish pre-metastatic niches in
lymph nodes and organ-specific distal sites.42
2.3. Extracellular vesicles as a novel type of liquid biopsies
EVs are released by the vast majority, if not all, cell types in the
body; hence blood and other biofluids contain a mixture of EVs
released by various cells. Multiple studies have shown that the
levels of EVs in biofluids of cancer patients are higher than in
healthy controls.43–50 Furthermore, some studies suggest that
elevated levels of EVs are associated with the presence of minimal
residual disease, therapy failure and disease progression, and that
the level of EVs significantly drops after surgery.51,52 These find-
ings support the idea that the presence of cancer stimulates the
release of EVs; however, whether these EVs are produced by
cancer cells themselves or represent a systemic response to the
disease or treatment is still a matter of debate.18,53 Moreover,
increased levels of EVs have been found in the blood of patients
with various non-cancer diseases and physiological stress condi-
tions, suggesting that the release of EVs is a common response to
various stress cues.18 Thus, the EV level per se does not appear to
be a highly specific biomarker of cancer. On the other hand, EVs
isolated from plasma and other biofluids of cancer patients have
been shown to contain cancer cell-derived molecules such as
truncated epidermal growth factor receptor EGFRvIII,54 mutated
DNA and mRNA fragments and cancer-specific splice variants and
fusion transcripts,55–57 as well as cancer-associated mRNA, protein
and miRNA signatures.55,58 These findings have raised the idea
that cancer-derived EVs may serve as a source of RNA, protein,
lipid, DNA and metabolite-based biomarkers for early detection of
cancer, monitoring cancer progression and tracking tumor evolu-
tion (Table 1 and Fig. 1).
EVs may have several advantages over CTC, cfDNA or cfRNA-
based liquid biopsies. At first, they are more abundant than CTCs
and therefore may reflect intratumor heterogeneity better than CTCs
and/or be easier to detect at earlier stages of cancer, in particular for
tumors that release few CTCs, such as tumors of the central nervous
system.18,59,60 Secondly, in contrast to vesicle-free cfDNA and cfRNA,
EVs contain molecular signatures reminiscent of their parental cells
and protect their cargo from degradation.18,59 Indeed, several studies
have shown that EV-enclosed DNA yields higher sensitivity and
specificity for detecting KRAS, EGFR and BRAF mutations than total
circulating cfDNA.56,61–63 Our recent study demonstrated that some
miRNA biomarkers show better diagnostic performance if tested in
EV-enclosed RNA as compared to total circulating cfRNA.64
Currently, one of the main biological challenges in develop-
ing EV-based blood tests is that the proportion of cancer-
derived EVs in the total pool of EVs present in blood is low
and highly variable among patients leading to high variability
in the assay performance. One of the possible solutions is to
isolate specific EV subpopulations that may serve as biomar-
kers by themselves or may be enriched with cancer-derived
molecules. For instance, glypican-1 (GPC1) has been identified as
a highly specific marker of pancreatic cancer-derived EVs and the
levels of GPC1-positive EVs have been shown to have diagnostic
and prognostic value in pancreatic cancer.65,66 Similarly,
prostate-specific membrane antigen (PSMA) has been used for
the isolation of prostate-specific EVs. Although PSMA is a
prostate-specific, not prostate cancer-specific, protein, the
plasma levels of PSMA-positive EVs could discriminate prostate
cancer from benign prostatic hyperplasia and correlate with the
aggressiveness of the disease.67,68 Conceivably, these EV sub-
populations are also enriched in cancer-derived molecules.
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Furthermore, EVs have been detected in various other biofluids
including lymph, saliva, urine, cerebrospinal fluid, breast milk
and bronchoalveolar lavage fluid;56,69–71 hence these biofluids
may serve as organ-specific liquid biopsies for cancers that are
in contact with the given biofluid.
2.4. State-of-the-art techniques to analyze EV biomarkers in
biofluids
The use of omics methodologies such as mass spectrometry
for protein, lipid and metabolite quantification, and next
generation sequencing for quantification of nucleic acids, has
led to the discovery of numerous EV-based biomarkers for
several diseases.18,72,73 In the biomarker development pipeline,
the validation phase follows the discovery phase. In this phase,
the ability of the biomarker to separate specific patient groups
using larger and independent patient cohorts is verified, and
the best analytical platform to quantify the biomarker is
established. In fact, the quantitative verification of the biomar-
kers identified in the discovery phase studies is considered a
bottleneck in biomarker development. The analytical method
should be able to quantify the biomarker(s) in a specific, highly
reproducible, robust, fast and cheap way in order to facilitate
the implementation of the biomarker test in the clinic. Con-
ventional techniques to analyse EVs include methods such as
nanoparticle tracking analysis (NTA), flow cytometry, dynamic
light scattering (DLS), western blotting (WB) or immunoassays
among others (Table 2). These techniques can provide valuable
information about EV size, concentration or specific markers,
as summarized in excellent reviews where readers are referred
to for detailed information.10,11,74,75 On the other hand, mass
spectrometry and next generation sequencing, although very
useful for the discovery of biomarkers, are currently not widely
used in clinical laboratories. Instead, PCR-based tests, for the
quantification of nucleic acids, and immunological methods,
mainly enzyme linked immunosorbent assays (ELISA), for the
quantification of proteins, are part of clinical lab routines and
are commonly used for diagnostic purposes (Table 1). These
methods have high sensitivity and do not require complex
equipment. In terms of EVs, a polymerase chain reaction
(PCR)-based test for the detection of RNAs in urinary EVs that
can reduce the number of unnecessary biopsies has already
been commercialized.76 The potential of lateral flow immunoas-
says (LFIAs) for detection of protein biomarkers in EVs has also
been shown since a LFIA using the membrane proteins tetra-
spanins as targets is able to detect purified EVs from human
plasma and urine.77 LFIAs are based on similar principles as
ELISA tests, in which a capture antibody is immobilized on a
solid phase, and are ideal POC tests because they require few
resources. Interestingly, immunoisolation is particularly suitable
for liquid biopsies of specific cancer types and several micro-
fluidic devices based on this principle are being developed.78
In addition to the analytical approaches, the standardization
of the preanalytical procedures is essential for robust bio-
marker quantification and data interpretation.85 It is critical
Fig. 1 EV-based biomarkers in liquid biopsies. Human blood and other
biofluids contain a mixture of EVs released by various cell types. Impor-
tantly, EVs isolated from cancer patients’ biofluids contain various cancer-
derived molecules. This has raised the idea that EVs may serve as a source
of protein, RNA, DNA, lipid and metabolite based cancer biomarkers.
Moreover, several studies indicate that the levels of EVs are increased in
cancer patients. Therefore, the count of specific EV subpopulations in
biofluids may be used as a biomarker on its own. Some elements of the
figure originate from Servier Medical Art image bank.
Table 2 Summary of conventional techniques used to characterize EVs. WB = Western Blot; ELISA = Enzyme linked immunosorbent assay; NTA =
Nanoparticle tracking analysis; DLS = dynamic light scattering; Ab = Antibody
WB ELISA Flow cytometry NTA DLS
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that the collection and storage of biofluids follows specific
guidelines.86 Moreover, when working with EVs, the way in which
vesicles are isolated/purified should be carefully investigated. The
main goal of EV isolation is to concentrate the molecular signal
contained in the EVs and/or remove contaminants that may mask
the signal or perturb the analytical measurement. At the moment,
several methods to isolate/purify EVs exist, including ultracentri-
fugation, size-exclusion chromatography, precipitation, immuno-
isolation, microfluidics or filtration.78,87–89 These methods have
advantages and disadvantages that have to be considered in
relation with the specific biofluid, the biomolecule that is going
to be measured and the analytical method that is going to be
used. In fact, it has been shown that the yield and purity of EVs
significantly vary between different isolation methods.90,91 There-
fore, the isolation of EVs may introduce a potential error in the
quantification of biomarkers. Thus, ideally, a routine test should
not require a prior isolation of EVs from the biofluids. This could
be possible if the EV-associated biomarker is very abundant and/
or the quantification method is very sensitive and not affected by
other materials found in the biofluid. This strategy has already
given promising results. For example, Duijvesz et al. have devel-
oped a highly sensitive time-resolved fluorescence immunoassay
(TR-FIA) for capture/detection of prostate cancer derived EVs that
allows the quantification of EV proteins directly from urine.46
Other example is the ExoScreen assay, which is able to detect EVs
directly in serum using two antibodies to capture the vesicles that
are then detected using photosensitizer-beads.92
3. Development of nanoparticle-based
biosensors
Currently, a nanomaterial can be defined as ‘‘a natural, incidental
or manufactured material containing particles, in an unbound
state or as an aggregate or as an agglomerate and where, for 50%
or more of the particles in the number size distribution, one or
more external dimensions is in the size range 1–100 nm’’.93 On
the other hand, the International Organization for Standardiza-
tion defines a NP as ‘‘a material with all external dimensions in
the nanoscale, where the lengths of the longest and the shortest
axes of the nano-object do not differ significantly’’. In this
review we will mainly focus on the use of NPs for the develop-
ment of biosensors with enhanced performance. Materials
on the nanometre scale have unique optical, electronic, and
magnetic properties that are different from the bulk material.
Of particular interest is the possibility of changing their physico-
chemical properties by tuning the shape and size of many NPs.
For instance, important features that can be tailored on demand
are the surface plasmon resonance (SPR) of gold NPs (AuNPs), the
emission wavelength of carbon nanotubes (CNTs) or Quantum
Dots (QDs), or the magnetic properties of magnetic nanoparticles
(MNPs). One general advantage of NPs is their large surface area
to volume ratio, enabling the attachment of an enhanced number
of biomolecules.94,95 In addition, as NPs and biomolecules have
similar sizes, they can interact more effectively. NPs therefore
hold huge interest in biomedical applications. Indeed, NP-based
biosensors have become one of the major topics in the field of
diagnostics.96,97 The use of NPs allows the development of
devices with increased sensitivity and lower limits of detection
(LODs), features with growing interest in the sensing field.
Furthermore, lab-on-a-chip based assays allow the rapid analysis
of low amounts of samples, thus reducing clinical care costs.77
In the field of EVs, several detection platforms have been
reported based on diverse sensing techniques, such as colori-
metry, fluorescence, SPR, Surface-enhanced Raman spectroscopy
(SERS), electrochemistry or nuclear magnetic resonance, showing
the potential of NPs in diagnostics.79,98,99 These methods, along
with their advantages and disadvantages, will be discussed in the
next sections.
3.1. Functionalization of NPs with antibodies and aptamers
When developing biosensors, antibodies (Abs) and aptamers
are two of the most commonly used molecular recognition
biomolecules. These molecules are generally coupled to NPs in
order to selectively recognize EVs. The most common targets
to identify and detect EVs are protein markers such as tetra-
spanins (CD63, CD9, CD81), ALIX or TSG101.3 Moreover, EVs
also contain specific markers directly related with their cellular
origin; the analysis of these antigens could be used to detect EVs
derived from cancer cells for instance.2 Aside from proteins, EVs
also contain RNAs; among all RNA species, miRNAs are in general
very abundant, and can be used as biomarkers,100 although
aptamers and Abs are not commonly used to target them.
Different types of Abs or Ab-derived fragments can be used
to functionalize NPs to detect EV antigens.101 The most widely
used is Immunoglobulin G (IgG). IgG consists of four poly-
peptide chains linked together by disulphide bonds, forming a
Y-shaped structure (Fig. 2a and b). The IgG structure can be
subdivided into two parts, the antigen binding fragment (Fab)
and the constant fragment (Fc) (Fig. 2b). The Fab region (arms
of the Ab) contains the antigen-binding site, which confers
antigen specificity. A single IgG has two antigen-binding sites
that are found at the extremity of the arms. In order to improve
the biosensor performance, it is highly important to leave these
antigen binding sites available, so that they can interact with
their antigens. One of the key factors to develop a reliable
biosensor, therefore, is the technique used to immobilize the
Abs on the NP surface, as the selected methodology can impact
the Ab structure and activity, and ultimately the biosensor
sensitivity.102,103 The methodologies used to functionalize Abs
on NPs are based on physical adsorption, covalent binding or the
use of specific adaptor molecules (Fig. 2c–g).104–106 Generally,
strategies that provide a better orientation of the Ab on the NP
surface and without involving the antigen-binding sites will result
in a better outcome than strategies providing a random orienta-
tion of the Ab.107 Here we present some of these strategies, which
could be implemented to build biosensors to detect EVs.
One of the most common strategies to covalently link Abs
to NPs is to use the amine groups from the Abs (Fig. 2d).105
However, using this approach, Abs will be immobilized with a
random orientation, as some Abs will be well oriented, while
others will not have their antigen binding sites available.
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Moreover, taking into account the different pKa values of the
amine groups of the Ab, at the pH conventionally used for this
kind of reaction, the most reactive amine groups are the
terminal ones. Unfortunately, these moieties are located in
the antigen binding area, and their use could reduce the
recognition efficacy of the Abs. In order to overcome this
limitation, other strategies have been developed to improve
the orientation of the Abs. For instance, Puertas et al. demon-
strated that by binding the Ab on MNPs through its sugar
moieties (located in the Fc region, Fig. 2e), by their partial
oxidation and formation of a Schiff base, the LOD of a LFIA
could be greatly improved.109 Other works suggested the use of
bioorthogonal click chemistry to functionalize the surface of
NPs with Abs. The cycloaddition between 1,2,4,5-tetrazines (Tz)
and trans-cyclooctene (TCO) is a straightforward method to
bind Abs on the NP surface.110 Furthermore, it is fast, catalyst
free and chemoselective. Abs modified with TCO have been
used to detect cells and pathogens before being coupled with
MNPs functionalized with Tz.110,111 When compared with
direct Ab binding, the use of bioorthogonal click chemistry
yielded higher sensitivity. This strategy could enhance the
signal to a greater extent than other two-step labelling
strategies that are routinely used, such as the coupling of
avidin-modified Abs with biotin-conjugated MNPs. In addition,
consecutive steps of orthogonal chemistry can further amplify
the signal and increase the sensitivity.112
However, all these examples imply the chemical modification
of the Abs. This modification can ultimately affect Ab structure
and activity. To overcome this concern, other strategies have
been proposed. Some groups have demonstrated that unspecific
reversible interactions between the Ab and the NPs can be
used to orient the Ab before performing a covalent coupling
(Fig. 2g).113,114 In these cases, the incubation pH can be selected
to orient the Ab, as the net protein surface charge depends on
the isoelectric point of the Ab.115 Puertas et al. described this
strategy to bind different types of Abs to MNPs, demonstrating
that in all cases the activity was higher than when using a
random conjugation.12 This approach has been also used for
the binding of Abs to AuNPs116 and multiwalled carbon nano-
tubes (MWCNTs),117 showing an improvement of the analytical
performance of the biosensors when using this approach.
Aside from the orientation, the Ab density is also an important
factor to take into account.114,118 Although the use of adaptor
molecules (Fig. 2f) could provide worse Ab coating, the improve-
ment on the presentation is able to enhance its activity.119 On the
other side, Van der Heide et al. described that using protein A as
an adaptor molecule resulted in higher Ab per AuNP and higher
binding efficacy when compared to random immobilization
through the most reactive amine groups.120
Aptamers are synthetic single-stranded oligonucleotides
(DNA or RNA) that bind to target molecules, such as proteins
or nucleic acids, with high affinity and selectivity. Thus, they
Fig. 2 (a and b) Schematic cartoon showing (a) the Y-shaped structure of an Ab (which is the ligand to be attached to the NP); the two light chains
(variable regions) and the heavy chains (constant regions) are coloured in blue and red respectively. The green colour represents the antigen binding sites.
The purple colour represents groups which can be used for attachment to NPs. (b) Three-dimensional model of an Ab from X-ray crystallography studies.
(c–g) Schematic representation of different strategies used to functionalize NPs with Abs: (c) electrostatic adsorption; (d) covalent binding via amine
groups on the Ab; (e) covalent binding via carbohydrate groups on the Ab; (f) use of adaptor biomolecules (streptavidin–biotin, Protein G); (g) ionic
adsorption plus covalent binding. Adapted from ref. 105 with permission from Elsevier. (h) Schematic illustration of a nanotetrahedron-assisted
electrochemical aptasensor. Aptamer-containing nanotetrahedra were immobilized via three thiol groups onto the gold electrodes for direct capture of
exosomes in suspension. R: reference electrode area; W: working electrode area, with a diameter of 4 mm; C: counter electrode area. Adapted with
permission from ref. 108. Copyright (2017) American Chemical Society.
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have been used in many biomedical applications, including
biosensing. Aptamers are selected from an oligonucleotide
library by Systematic Evolution of Ligands by Exponential
Enrichment (SELEX), a process that can be automatized.121,122
Target recognition and subsequent binding is based on electro-
static and hydrophobic interactions and the three-dimensional
structure that they adopt. Compared to Abs, aptamers are
thermally stable, have a smaller size, are more flexible and lack
immunogenicity.123,124 When developing biosensors, the den-
sity of the aptamers on the surface of the support can be a
critical factor. For instance, a dense coating could end with a
high steric crowding and aptamer entanglement, thus resulting
in poorer accessibility.125 It has been suggested that immobiliza-
tion through the 30 end or the addition of a linker can improve
the target binding, presumably due to a decreased steric hin-
drance or an improved folding.126 In this sense, the use of DNA
nanotetrahedron structures to functionalize the aptamers can
greatly improve the accessibility and binding ability of aptamers
to their targets.127,128 For instance, Wang et al. developed an
electrochemical biosensor to detect EVs where the aptamers
were oriented using a tetrahedron structure (Fig. 2h).108
The sensitivity of the aptasensor was increased 100-fold when
compared with that obtained using single-stranded aptamers.
3.2. NP-based biosensors for EV analysis
3.2.1. Lateral flow immunoassays. LFIA is a well-established
and versatile technology used to detect and quantify analytes by
performing an immunochromatographic assay using a porous
membrane. These assays are good candidates as POC diagnostic
sensors, presenting many advantages in comparison with other
analytical methods used in clinical care. In addition to being
rapid and cost-effective diagnosis devices, these tests are easy to
use since unskilled personnel can perform them, and additional
processing or external equipment is not required.
In a typical LFIA sandwich assay, the sample is added to the
sample-pad and it migrates by capillarity to the conjugate-pad.
There, the analyte finds a conjugate composed of the detection
Ab conjugated to particles such as latex beads or AuNPs
(Fig. 3a).129,130 This complex flows through the nitrocellulose
membrane, where the analyte is now recognised by the capture
Ab immobilized at the test line (TL). Finally, the excess of
conjugate reaches the control line (CL) where a secondary Ab
Fig. 3 (a) Schematic representation of a typical LFIA when the target analyte is present (left panel). Naked eye detection of a negative and positive test
(rigth panel). (b) Steric hindrance model for exosomal detection using LFIA: if a marker is abundant, the exosome is completely covered by the conjugate,
composed of the detection Ab functionalized on NPs. This reduces the availability of epitopes for the capture antibody present at the TL (left panel).
However, if the detection marker is scarcer, the exosome can be captured (right panel). (c) Model of the effect of the Ab concentration coupled to AuNPs.
When AuNPs are conjugated using a high concentration of the Ab, bigger aggregates are generated due to the crosslinking of Abs and exosomes. This
results in an impaired flow of the mixture on the strip and lower capture capacity (left panel). However, if the detection Ab is conjugated at lower
concentration, these complexes are not formed and each exosome can bind to several AuNPs, resulting in a better capture at the TL (right panel).
Adapted from ref. 133. Copyright (2018), with permission from Springer Nature.
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is located. This Ab recognizes the detection Ab, to indicate that
the test worked properly. The excess of sample migrates to the
absorbent pad (Fig. 3a).131,132 In summary, if the target analyte
is present, both the CL and the TL should appear and be
detected visually. If the target analyte is not present, only the
CL appears. The best well-known example of this bioanalytical
method is the human pregnancy test, based on the detection of
human Chorionic Gonadotropin (hCG) in urine.
LFIA test strips are therefore ideal candidates for EV detec-
tion when onsite analysis and simplicity are needed. Oliveira-
Rodrı́guez et al. developed a LFIA using tetraspanins as targets
to detect purified exosomes from cell culture supernatants of
Ma-Mel-86c melanoma cells.77 In this work the authors were
able to detect 8.54  108 exosomes per mL when combining
anti-CD9 and anti-CD81 as capture Abs and anti-CD63 as the
detection Ab. The detection Ab was labelled with 40 nm AuNPs.
In addition, and as a proof of concept, these authors managed
to visually detect 5 mg and 20 mg of plasma and urine-derived
exosomes respectively (commercial exosomes from healthy
donors) when different combinations of capture and detection
Abs against CD9, CD81 and CD63 were used. The Ab pair was
selected case-by-case depending on the different protein com-
position (localization and density of tetraspanins) present on
the exosomal surface.
Some studies have been carried out to evaluate the perfor-
mance of different NPs as labels, including AuNPs, carbon black
nanoparticles (CB) and MNPs. To select the best option, the
following parameters were compared: simplicity for the biocon-
jugate formation, stability over time and ease of visualization on
the strips.134 NPs were functionalized with anti-CD63 and tested
to detect EVs purified from plasma of healthy donors on strips
containing anti-CD9 as the capture antibody. Conjugates made
using AuNPs provided the best performance providing similar
sensitivity results as CB (E109 EVs per mL), but providing a
better fitting in the linear range. Moreover, AuNPs are easier to
get functionalized with Abs. In contrast, MNPs provided
low sensitivity and generated a retention-like line at the end of
the sample pad during the test. This study also explored a
multiple-targeted approach, incorporating the anti-CD81 Ab in
an additional capture line. Although single-targeted and multiple-
targeted detection provided similar LODs when using a reflec-
tance reader, the multiple-targeted detection had a broader
detection range. Since EVs from different origin express diverse
proteins on the surface, the incorporation of several test lines may
allow the detection of a broader range of EVs, opening the
possibility to study a concrete disease marker.
LFIA immunoassays using AuNPs as labels have been success-
fully employed for the detection of the endogenously expressed
tumour-derived antigen MICA (MHC class I chain-related
protein A) in exosomes.133 In this case it was very important
to consider potential competition events and steric effects in
LFIA assays, highlighting the importance of targeting scarce
proteins with the detection Ab present on the NPs (Fig. 3b). In
fact, targeting abundant proteins on the exosomal surface
could lead to steric impediments, impairing the subsequent
binding of the EVs with the capture Ab present at the TL.77
Furthermore, controlling the density of the detection Ab on the
AuNP surface allowed an improvement of the LOD, mainly
driven by the decrease of the aggregates because of the cross-
linking of Abs and exosomes (Fig. 3c). Taking into account all
these considerations, MICA-containing exosomes purified from
metastatic melanoma cell lines were detected at a concentration
of 5  1010 exosomes per mL, using anti-CD9 and anti-MICA Abs
as capture and detection Abs respectively. This was the first time
that canonical exosome markers as well as an endogenously
expressed tumour-derived antigen were detected using a LFIA.
In order to increase the sensitivity of LFIA sensors, an ampli-
fication step could be carried out. Wu et al. recently reported a
LFIA system using two different AuNP bioconjugates.135 The first
one included a monoclonal anti-CD9 Ab, while the second
bioconjugate was labelled with an anti-BSA Ab. The first biocon-
jugate recognized the exosomes and could be retained at the TL,
where a polyclonal anti-CD9 Ab was immobilized. The second
bioconjugate was then added, enhancing the staining, as the
first bioconjugate was blocked with BSA. This enhancement
improved the optical intensity of the red band formed by the
AuNPs on the TL. This system was used to detect isolated
exosomes from MCF-7 human breast cancer cells, showing a
LOD of 1.3  106 particles per mL, improving the sensitivity by
two orders of magnitude when compared to conventional LFIAs.
This LFIA was also successfully used for detecting MCF-7 exo-
somes diluted in ultracentrifuged foetal bovine serum, proving
its potential application in practical diagnostics.
Besides, it is also possible to detect exosomes through the
phospholipids present within their lipid bilayer. Dong et al.
studied this possibility using biotin-tagged 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSE-PEG-
biotin) to label exosomes through the strong hydrophobic
interaction of the fatty acid tails and the phospholipid
membrane.136 Based on the high affinity between streptavidin
and biotin, fluorescent nanospheres conjugated to streptavidin
(FNs-SA) were used as the detection system. On the other hand,
streptavidin was deposited at the TL in the LFIA test strips. In
this complex system, the biotin-EVs formed a complex with the
FNs-SA and with the streptavidin present at the TL. With this
approach, ultracentrifuged exosomes from human epithelial
Cal 27 cells were tested in the test strips and the minimal
detectable concentration using a portable UV lamp was
2.0  106 particles per mL. To collect the exosomes, however,
two rounds of ultracentrifugation were performed, consequently
increasing the time: (i) to isolate the exosomes from cell culture
media, and (ii) to remove the excess of reagents after labelling
with DSPE–PEG–biotin.
As an alternative to standard LFIA performed using Abs, a
lateral flow aptamer assay (LFAA) was proposed by Yu et al.137
This LFAA system was based on a competitive format, where in
the presence of exosomes, a CD63 aptamer functionalized on
AuNPs could interact with the CD63 exosomal proteins. On
the other hand, a CD63 aptamer complementary strand was
deposited at the TL. In the presence of exosomes, the aptamers
present on the AuNPs will interact with them, avoiding the
subsequent binding of the AuNPs to the TL. However, in the
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absence of exosomes, the AuNPs@aptamer could interact with
the complementary aptamer present at the TL, and give a
positive signal. Some parameters such as the concentration of
the blocking buffer to pre-treat the strips, the streptavidin
ratio to AuNP aptamer and the optimal incubation time were
optimized, reaching a LOD of 6.4  108 particles per mL for
exosomes derived from lung carcinoma A459 cells. Although
the idea of using aptamers instead of Abs could be advanta-
geous, further work should be conducted to validate this LFAA:
the addition of a CL on the test strips, the control of AuNP
aggregation and the possibility to assemble the strips in a more
reproducible way could all help to improve the system.
3.2.2. Colorimetric detection. Colorimetric detection of EVs
attracts significant interest due to its simplicity, as the colour
changes can be distinguished with the naked eye without
requiring sophisticated equipment. Thus, colorimetric platforms
are ideal candidates as POC biosensors. In some cases, however,
a relatively low sensitivity is obtained, and the colorimetric
signal has to be analysed using a spectrophotometer. In order
to enhance the signal, additional steps such as recombinase
polymerase amplification can be included, but this can compli-
cate the whole process. Many of these colorimetric biosensors
are based on the colour change associated to AuNP aggregation
or on the peroxidase (HRP)-like activity of some NPs and the
colour change induced when H2O2 and a substrate are present.
For instance, Chen et al. used positively charged MNPs to
isolate exosomes directly from plasma.138 The exosomes were
thereafter eluted using a high concentration of sodium chloride.
By performing this anion exchange-based isolation, exosomes
were recovered with high efficiency and high purity in a fast way.
Once isolated, aptamer-coated iron oxide nanoparticles were
added for the visual detection of exosomes (Fig. 4). The rationale
behind this experiment is that iron oxide nanoparticles have
weak intrinsic HRP-like activity, catalyzing a change of color
when 3,3,5,50-tetramethylbenzidine (TMB-substrate of peroxi-
dase) and H2O2 are present. Interestingly, the presence of
aptamers on the MNP surface increased the HRP-like activity
when compared with naked MNPs. In the presence of exosomes,
these aptamers could bind to them by molecular recognition,
getting desorbed from the MNP surface. Once the aptamers were
desorbed, a decrease in the catalytic activity of those NPs was
achieved, followed by a decrease in the colour change when TMB
and H2O2 were present. This color change could be detected by
UV-vis spectroscopy, and a linear correlation between the absor-
bance and the concentration of exosomes was found. The LOD of
this aptasensor was 7.0  106 particles per mL for exosomes
isolated from plasma (healthy donors) and 3.58  106 particles
per mL for exosomes isolated from simulated prostate cancer
(PCa) plasma samples. Similarly, single-walled carbon nano-
tubes (s-SWCNTs) coated with CD63 aptamers were used to
detect exosomes due to their HRP-like intrinsic activity.139 The
detection limit was 5.2  108 particles per mL and the whole
detection process took 40 minutes. Interestingly, no complex
technologies to enhance the signal were needed. Using graphitic
nitride nanosheets and a similar detection approach, a LOD of
13.52  108 particles per mL was reported.140
AuNPs are commonly used to design colorimetric-based
biosensors as their optical properties depend on the NP separa-
tion. Aggregation causes a shift in the extinction coefficient that
can be appreciated with a colour change. Taking advantage of this
phenomenon, Jiang et al. described a biosensor composed of
aptamers and AuNPs to detect and profile exosomes.141 Com-
plexation of aptamers with AuNPs protected them from aggrega-
tion at high ionic strength, as aptamers stabilized the AuNPs by
steric repulsion. When exosomes were present, these could bind
to the aptamers, resulting in the displacement of these ligands
from the AuNP surface, destabilizing the AuNPs under high ionic
strength conditions. This led to AuNP aggregation, resulting in a
red-to-blue color change that could be measured by UV-vis
spectroscopy. This sensor was used to differentiate exosomes
derived from different cancer cell lines depending on the CD63
expression level. Furthermore, the authors were able to detect
exosomal proteins restricted to a unique cell line by using an
aptamer that could bind to protein tyrosine kinase-7, over-
expressed in human acute lymphoblastic leukemia cells.
The aggregation of AuNPs in combination with other steps
to amplify the signal has also been reported. For instance, Liu
et al. designed a pair of DNA-labelled Abs that could bind to
the same target biomarker present on exosomes.142 Upon
synchronous recognition of the protein on the exosome surface,
the DNA strands could hybridize, generating a unique DNA
signal. This double-stranded DNA signal was amplified twice by
recombinase polymerase amplification combined with transcription-
mediated amplification to produce RNA strands. The RNA
products were proportional to the initial concentration of the
biomarker and could be detected by using oligonucleotide-
coated AuNPs, complementary to the RNA. RNA recognition
by the AuNPs promoted their aggregation and a red-to-blue
Fig. 4 Visible detection of exosomes. (A) Schematic representation of the
detection mechanism for the visible detection of exosomes. (B) UV-vis-
absorption spectra of TMB–H2O2 (curve a); TMB–H2O2 and iron oxide
NPs (curve b); TMB–H2O2 and aptamer–iron oxide NPs (curve c); and
TMB–H2O2, aptamer–iron oxide NPs, and exosomes (curve d). (C) Digital
images of TMB–H2O2 (image a); TMB–H2O2 and iron oxide NPs (image b);
TMB–H2O2 and aptamer–iron oxide NPs (image c); and TMB–H2O2,
aptamer–iron oxide NPs, and exosomes (image d). Reprinted with permis-
sion from ref. 138. Copyright (2018) American Chemical Society.
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color change that could be measured by absorption spectro-
scopy. With this technique, the authors demonstrated the
possibility to detect EGFR and Epstein–Barr virus latent
membrane protein 1 (LMP1)-positive exosomes derived from
nasopharyngeal carcinoma cells. Despite being more complex
than other colorimetric methods, the developed biosensor was
highly sensitive, and was able to detect 100 particles per mL.
DNA hybridization chain reaction (HCR) has also been used
to enhance the signal in colorimetric biosensors.143,144 Zhang
et al. used aptamer-conjugated MNPs to isolate exosomes from
cell culture media.144 Thereafter, a bivalent-cholesterol-labelled
DNA probe was incorporated into the exosome membrane
by hydrophobic interactions. The sticky end of this anchor
triggered an enzyme-linked HCR, where alkaline phosphatase
(ALP) was introduced. ALP enables the removal of the phosphate
group from ascorbic acid 2-phosphate to produce ascorbic acid,
which can further reduce Ag+. This reaction led to the formation
of silver shells on gold nanorods (AuNRs), and gave rise to a
change of colour that could be distinguished with the naked eye.
Interestingly, the colour changed from pink to brown, green or
purple with increasing concentration of exosomes. This allowed
an easier detection with the naked eye when compared with the
development of a unique colour. The reported LOD was 1.6 105
particles per mL by UV-vis spectroscopy. The sensor was tested
with plasma from donors, obtaining similar concentration
values as standard techniques, that is, ultracentrifugation
followed by NTA.
3.2.3. Fluorescence detection. Fluorescence spectroscopy con-
sists in the emission of light by atoms when, after a previous
excitation process, they return to the fundamental state. Fluores-
cent probes are widely used for optical bioassays and for the
development of fluorescence-based biosensors.145,146 Their trans-
duction method is based on the changes in the fluorescence
intensity or wavelength that occurs as a consequence of the
interaction of the fluorescent probes with the analyte. After this
successful interaction, it is possible to specifically quantify the
analyte by correlating the changes in fluorescence to the initial
concentration. In this review we will mainly focus on the use of
NPs with fluorescence properties as transduction elements.
Traditional assays for the identification of EVs by fluorescence
techniques are based on immunoassays, such as ELISA and
western blot, where Abs are coupled to organic fluorophores.147
These methods have excellent analytical performances, but
sometimes the stability of the fluorophore is compromised,
thus limiting their application. Fluorescent NPs have advanta-
geous optical properties, such as high photostability and quan-
tum yields, low photobleaching, size-tunable emission,
extremely broad excitation range and narrow emission which
allow large Stokes shift, that can overcome the limitations of
current fluorophores.148 These properties allow improving the
LOD and even enabling single molecule detection, making
fluorescence-based nanobiosensor devices more sensitive and
reliable when compared to the classic fluorescence detection
methodologies. Fluorescent NPs include NPs made with silica
and organically modified silica,149 metals,150 metal oxides,151
metal nanoclusters,152,153 upconversion NPs (UCNPs),154,155
organic polymers,156 quantum dots (QDs),157,158 silicon
quantum dots159 and different carbonaceous nanomaterials
such as carbon dots, carbon nanotubes, carbon nanoclusters
and nanodiamonds.160,161
Lanthanide-doped UCNPs undergo a non-linear photophysi-
cal process whereby low-energy radiation, usually in the near
infrared (NIR) range, is converted to higher-energy radiation, for
example, visible light (anti-Stokes shift). Thus, the fluorescence
emission of UCNPs takes place at shorter wavelengths than the
absorbed light. This feature makes them especially attractive for
biological applications and nanobiosensor development, since it
avoids the use of ultraviolet (UV) light, therefore minimizing the
autofluorescence of biological samples.162,163 UCNPs coupled to
aptamers have been used as energy donors in the development
of aptasensors based on Luminescence Resonance Energy Trans-
fer (LRET) in combination with other fluorophores or NPs that
act as acceptors. LRET and Fluorescence Resonance Energy
Transfer (FRET) are mechanisms that occur due to the very short
distance interaction between the energy levels of two lumines-
cent/fluorescent molecules in which the emission wavelength of
the donor molecule coincides with the excitation wavelength of
the acceptor molecule. In this way, the excited donor transfers its
energy to the acceptor, which emits a photon. Wang et al. used
tetramethyl rhodamine (TAMRA) and UCNPs functionalized with
two DNA aptamers to target the epithelial cell adhesion molecule
(EpCAM) present on the exosome membrane of some cell
lines.164 After the aptamer–exosome binding, both DNA strands
got closer and the distance between the energy donor (UCNPs)
and the acceptor (TAMRA) was reduced, promoting the LRET
process (Fig. 5). Due to the coincidence between the emission
wavelength of the donor and the excitation spectrum of the
acceptor, the excitation of UCNPs by IR light produces a UV
emission that excites the TAMRA molecule, leading to a yellow
emission (585 nm) that is linearly correlated with the exosome
concentration. This LRET sensor reached a LOD of 8  104
particles per mL.
Fig. 5 Aptasensor based on LRET between UCNP donor and TAMRA
acceptor for highly sensitive detection of exosomes. The two DNA strands
from the EpCAM aptamer are labeled with UCNPs and TAMRA, which get
closer to each other when recognition of EpCAM exosomes occurs.
The LRET fluorescence response enables the quantitative detection of
exosomes. Reprinted with permission from ref. 164. Copyright (2019)
American Chemical Society.
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The possibility of immobilizing this type of sensors in a user-
friendly POC format makes them even more interesting. This is
the case of an exosomal aptasensor based on a LRET system that
used AuNRs as the acceptor and UCNPs immobilized on a paper
support as the donor.165 As before, the sequence of the CD63
aptamer was split into two different fragments, and AuNRs and
UCNPs were decorated with only one of the fragments. In the
presence of exosomes, the CD63 protein present on their surface
was combined with both strands of the aptamer bound to AuNR
and UCNP-paper respectively; this reduced the distance between
acceptor and donor, allowing the LRET to take place. The
analytical signal was the quenching effect produced by AuNRs
over the green luminescence of UCNPs under IR excitation,
reporting a LOD of 1.1  106 particles per mL.
QDs are also widely used in fluorescence-based biosensing,
due to their high emission quantum yield, size tunable emission
profiles with a narrow spectral band and unique photophysical
properties.166 Bai et al. used QDs to build a bead-based exosome
microfluidic chip for exosome isolation and multiplexed
detection.167 Anti-CD9-labeled magnetic beads were used to
isolate exosomes, while three QD probes labelled with Abs to
detect tumoral markers were used for multiplexed detection of
exosome surface markers (carcinoma embryonic antigen, CEA;
Cytokeratin 19; Progastrin-releasing peptide, proGRP). With this
novel microfluidic immunoassay system and using an inverted
fluorescence microscope, it was possible to discriminate
between plasma-derived exosomes from lung cancer patients
and healthy controls. Further, minimal differences were found
between these experimental results and clinical data obtained
using traditional methods for the detection of CEA in real
samples. Although CdSe-based QDs are the most used QDs,
works that use other kind of QDs as fluorescent labels for EV
detection combined with fluorescence microscopy have been
reported: InP/ZnS QDs,168 silicon QDs169 and gold–carbon
dots170 among others.
Although metallic NPs can be used as fluorescent labels
because of their intrinsic fluorescence, not many works have
employed them to detect EVs. He et al. used CuO NPs modified
with CD63 aptamers to form sandwich complexes with exo-
somes previously isolated with magnetic beads.171 These com-
plexes were subsequently dissolved in acidic medium to obtain
copper(II) ions which were thereafter reduced to fluorescent
CuNPs (copper nanoparticles) in the presence of sodium
ascorbate and poly(thymine) (Fig. 6a). CuNPs’ concentration
and fluorescence were proportional to the exosome content,
obtaining a LOD of 4.8  107 particles per mL. Many times the
fluorescence of these metallic NPs is not intrinsic, but comes
from ligands placed on their surface during their synthesis. For
instance, Gao et al. designed a complex exosome detection
method using a rolling circle amplification (RCA) reaction.172
A series of long DNA hairpin structures with components such
as CD63 aptamer, linker and spacer sequences were obtained
using the RCA reaction. In the presence of exosomes, the RCA
product could attach to the exosomal membrane, opening its
hairpin structure and exposing a linker sequence. A fluorescent
AuNP-linker/complementor bioconjugate (AuNP-L/cL) could
then pair with this linker sequence by toehold-mediated strand
displacement, releasing the fluorescent cL probe. The fluorescence
signal was proportional to exosome concentration, reaching detec-
tion limits in the order of 1  108 particles per mL.
Other metallic materials reported in the literature are
MXenes, new nanosheet structures that combine transition
metal carbides and thus metallic conductivity with hydrophilic
nature due to their oxygen or hydroxyl terminated surfaces.
This property facilitates their interaction with biomolecules,
positioning them as highly interesting nanobiointerfaces for
the development of biosensors, where they are used as nano-
quenchers.174 The detection mechanism is based on a FRET
phenomenon in which a fluorophore (donor) transfers energy
to the nano-quencher (acceptor) by distance-dependent fluores-
cence quenching coupling. When this distance increases, the
fluorescence of the donor is recovered, as the nano-quencher
does not act anymore. This phenomenon has been exploited to
detect EVs using a fluorescent-labelled Cyanine (Cy3)-CD63
aptamer and Ti3C2 MXenes as the 2D nano-quencher
interface.175 MXenes could absorb the aptamer by chelation
interaction of the hydrogen–metal bond, turning off the Cy3
fluorescence. When exosomes were added, the Cy3 fluores-
cence was recovered because of the release of the aptamer from
the nanosheet, as a consequence of its higher affinity with the
surface of the exosome. A LOD of 1.4  103 particles per mL was
obtained. This FRET mechanism has been also exploited to detect
EVs using s-SWCNTs, MoS2–multiwall carbon nanotubes (MWCNT),
graphene oxide (GO) or MoS2 nanosheets (Fig. 6b).
139,173,176–178
Finally, polymeric NPs such as lanthanide chelate-doped
polystyrene beads are also being used as sensing platforms.
Islam et al. used these NPs with long-lifetime fluorescence when
compared with the fluorescence of highly effective markers, such
as europium, to develop a NP-based time resolved fluorescence
immunoassay (NP-TRFIA).179 The polystyrene beads were con-
jugated with Abs or lectins against tetraspanins present on the
exosome surface. Anti-CD9 Abs were immobilized on the surface
of a microwell plate so that they could capture the exosomes.
Thereafter, polystyrene beads were added and TRF detection was
performed. It was demonstrated that beads coated with lectins
showed a 2–10 fold higher signal when compared to Eu-chelates.
EVs from minimally processed urine samples were detected with
a LOD of 0.03 ng mL1. Another example for the development
of a fluorescence-based immunosensor was the use of poly-
diacetylene liposomes conjugated to anti-CD63 Abs.180 Based
on the optical properties of polydiacetylene, the interaction
with exosomes isolated from human plasma led to changes in
the fluorescence signal, achieving a detection limit of 3  108
particles per mL.
3.2.4. Electrochemical detection. In electrochemical bio-
sensors the signal is generated as a consequence of an electro-
chemical interaction (redox reaction) between the analyte and
the electrode surface. This influences the electric or potential
current, and ultimately generates an electronic signal with
the help of a transducer. Electrochemical biosensors such as
potentiometric, amperometric, and voltammetric ones have
notable advantages such as low detection limits, high stability,
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real-time response and reproducibility, together with a high
surface to volume ratio, which facilitates electronic transfer-
ence and direct attachment of biomolecules.181 Nanomaterials
based on noble metals, metallic oxides,182 QDs, carbon-based
materials such as CNTs183 and some polymeric biomaterials184
have interesting properties that make them attractive to be
exploited in this type of biosensors. They can be used directly
because of their own redox properties, or indirectly if they have
electrocatalytic properties toward other species.185
For instance, Boriachek et al. used QDs and a voltammetric
immunoassay for the electrochemical detection of exosomes.186
To this end, biotinylated CdSe QDs were functionalized with
Abs against HER-2 and FAM134B, as potential markers of
breast and colon cancer respectively. After acid dissolution of
the CdSe QDs and anodic stripping voltammetric quantifica-
tion of Cd2+, a sensitive detection of 105 exosomes per mL was
achieved in exosomes derived from serum samples of patients
with colorectal adenocarcinoma. The same authors developed a
more sophisticated dual isolation and electrochemical detection
using gold-loaded ferric oxide nanocubes (Au-NPFe2O3NCs)
functionalized with CD63 Abs. Exosomes derived from BeWo
placental choriocarcinoma cells were first isolated using these
magnetic nanocubes (Fig. 7a and b).187 The exosomes were
subsequently transferred to screen-printed electrodes previously
functionalized with an anti-placental exosome Ab. The oxidation
of TMB in the presence of H2O2 was accomplished because
of the HRP-like activity of the Au-NPFe2O3NCs. Subsequent
addition of stop solution produced diimine, a product that is
electroactive and stable. Naked eye detection along with electro-
chemical quantification reported a LOD of 103 exosomes per mL.
In addition, electrochemical biosensors based on metallic NPs
have been successfully applied for multiplexing. For instance,
Zhou et al. designed an electrochemical sensor for exosome and
microsome detection by direct electro-oxidation of AgNPs and
CuNPs labelled with anti-EpCAM and anti-PSMA respectively.
The platform required only 25 mL of sample and exhibited a LOD
of 50 exosomes per sensor.188
Electrochemiluminescent (ECL) biosensors are based on
the emission of light (chemiluminescence) when an electro-
chemical reaction takes place, commonly on an electrode.
Fig. 6 (a) Direct capture and rapid detection of exosomes using a copper-mediated signal amplification strategy. After the formation of sandwich
complexes (Magnetic Bead–exosome–CuO NP), the unbound CuO NP probes are separated by a magnet and dissolved by acidolysis to convert CuO
NPs into copper(II) ions (Cu2+) and reduced to fluorescent copper nanoparticles (CuNPs) by sodium ascorbate in the presence of poly(thymine). The
fluorescence intensity of CuNPs increases with the increase of Cu2+ concentration, which is directly proportional to the concentration of exosomes.
Reprinted with permission from ref. 173. Copyright (2018) American Chemical Society. (b) A MoS2–MWCNT fluorescence nanosensor based on FRET in
which the fluorophore-CD63 (donor) transfers energy to the nano-quencher MoS2–MWCNT (acceptor) and provides an ‘‘on–off’’ sensor to detect the
exosome–antibody recognition. Reprinted with permission from ref. 173. Published by the Royal Society of Chemistry.
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Therefore, this methodology combines electrochemical and
luminescence techniques, and merges the advantages of both
methods.190 The use of NPs to build this type of sensors offers
advantages such as amplification of the ECL signal, or the
possibility to use NPs as the sensor nucleus (ECL comes directly
from the NP) or as resonance energy transfer acceptors (NPs
and fluorophores-combined ECL). Zhanga et al.189 developed
a sensor using Ti3C2 MXene nanosheets to enhance the ECL
signals of luminol. Exosomes were first captured onto an
electrode surface functionalized with an aptamer to recognize
the exosomal EpCAM protein. On the other side, Ti3C2 MXene
nanosheets were modified with CD63 aptamers to recognize the
exosomes that were already captured (Fig. 7c). The catalytic and
conductivity characteristics of the nanosheets together with the
possibility of improving the electron transfer on the electrode
interface led to a luminol amplification signal. A LOD of
1.25  105 particles per mL for EVs derived from MCF-7 cells
was reported. Similarly, black phosphorus quantum dots
(BPQDs) functionalized with MXenes have also been used
to develop a ECL biosensor to detect EVs with a LOD of
3.7  104 exosomes per mL.191 Other examples could be found
in the literature reporting ECL aptasensors for exosome detec-
tion using mercaptopropionic acid (MPA)-modified Eu3+-doped
CdS nanocrystals (MPA-CdS:Eu NCs) functionalized with CD63
aptamers.192 MPA-CdS:Eu NCs were immobilized on glassy
carbon electrodes and they behaved as ECL emitters in the
presence of H2O2. Exosomes were added and the ECL intensity
recorded. Subsequently, a DNA sequence that could fold into a
G-quadruplex/hemin DNAzyme was introduced. This structure
had HRP-like activity, and could catalyze the reduction of H2O2.
This decomposition of H2O2 resulted in a decrease of the ECL signal
of the MPA-CdS:Eu NCs. A LOD of 7.41  104 exosomes per mL
for MCF-7 breast tumor cells was achieved. The platform was
applied to detect exosomes in serum, showing potential appli-
cation in real sample diagnosis.
3.2.5. Surface enhanced Raman spectroscopy. Raman spectro-
scopy based biosensors can be used to detect and analyse the
composition of EVs. This spectroscopy technique is based on the
light that is inelastically scattered from a sample when a source
of light (laser) interacts with it.193 The scattered photons have a
Fig. 7 (a and b) Electrochemical biosensor based on dual isolation and electrochemical detection using Au-NPFe2O3NCs. (a) Schematic representation
of the assay for direct exosome isolation and detection from cell culture media. In this method, the Au-NPFe2O3NCs were initially functionalized with
a generic antibody (CD63) and dispersed in cell culture media to capture bulk exosomes. After magnetic capture and purification, exosome-bound
Au-NPFe2O3NCs were transferred to specific Ab-modified, screen-printed electrodes. (b) The HRP-like activity of Au-NPFe2O3NCs was then used to
achieve naked-eye detection along with electrochemical quantification of specific exosomes present in cell culture media. Reproduced from ref. 187
with permission from The Royal Society of Chemistry. (c) The principle of an ECL biosensor for exosome detection using Ti3C2 MXene nanosheets to
enhance the signal. Reprinted from ref. 189. Copyright (2018), with permission from Elsevier.
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different wavelength than the incident photons, and this
difference in energy depends on the chemical bonds present
in the sample. By measuring the wavelength of these scattered
photons, it is possible to obtain a detailed molecular
fingerprint.194 The main advantages of this technique are the
high spatial resolution, combined with a non-invasive label
free methodology. By contrast, the Raman scattering effect is
generally very weak.
The presence of metals can solve this weakness, as they can
enhance the signal up to 1015 times, depending of the geometry
(thickness, size and shape) and the composition of the metal
nanostructures.195,196 This technique is referred to as SERS
(Fig. 8).197 SERS is a plasmonic-based spectroscopic technique
that combines a laser with the optical properties of metallic
nanostructures to obtain detailed chemical information of
molecules adsorbed or attached to them.198 The technique is
supported by the formation of regions of intense field enhance-
ment, caused by local surface plasmon resonances (LSPR) at the
metal–dielectric interface.199 LSPR excitation will induce an
enhanced electromagnetic field, increasing the number of
scattered photons in the presence of a Raman-active molecule.
Therefore, SERS is a powerful technique that can provide
particular signals in complex environments, offering at the
same time high sensitivity and multiplexing ability. Further-
more, it allows the analysis of small sample concentrations
with short acquisition times, which is ideal for the measure-
ment of biological samples in the clinic and medical research.
Because of these advantages, SERS biosensors comprising NPs
are currently being used to detect and identify the molecular
differences between different groups of EVs.
SERS biosensors can be divided into two types:8 (i) solution-
based, where an EV is generally captured between 2 NPs and
afterwards deposited on a substrate to perform the measurement
(Fig. 9a and b); (ii) solid-based, where an EV is directly captured on
a substrate where the measurement will be done. Glass slides
non-coated or coated with a metal layer or NPs (to increase the
sensitivity) can be used as the substrate (Fig. 9c and d).
Zong et al.203 were the first to report a SERS-based strategy to
detect exosomes from tumor cell lines. The methodology used
magnetic beads and SERS nanoprobes (Au@Ag NRs@SERS
reporter) functionalized with specific Abs able to recognize
CD63 and the tumoral marker HER2 (epidermal growth factor
receptor-2). When exosomes were present, both the magnetic
beads and SERS nanoprobes attached to the exosome, forming
a sandwich type immunocomplex. Magnetic beads were then
used to separate the exosomes from the cell media and SERS
signals were detected in the isolated vesicles. Exosomes derived
from a breast cancer cell line were specifically detected,
reaching a LOD of 6  104 exosomes per mL. Going a step
forward, Wang et al. used aptamers and the multiplexing ability
of SERS to simultaneously detect multiple exosomes.204
Magnetic beads coated with a layer of silica and a layer of Au
(MB@SiO2@Au) were functionalized with CD63 aptamers
to capture extracellular vesicles. On the other hand, AuNPs
decorated with a SERS reporter and with a specific aptamer
were fabricated (AuNP@aptamer) as SERS probes. To allow
multiplexing, three kinds of SERS probes were synthesized
using different SERS reporters. Breast cancer (SKBR3), prostate
cancer (LNCaP) and colorectal cancer (T84) cells were selected
as model cells, and the aptamers designed accordingly to target
proteins overexpressed in exosomes derived from these cancer
cell lines. If only one type of exosomes is present, its specific probe
will recognize it, forming a sandwich-type apta-immunocomplex
containing MB@SiO2@Au, the target exosomes and the SERS
probes. After magnetic separation, SERS signals of the super-
natant are measured, finding a decreased signal of this probe
when compared with the other SERS probes. If three populations
of exosomes are present, the signal of the three types of probes
will decrease. The possibility to detect and distinguish different
types of exosomes at the same time was demonstrated experi-
mentally. The methodology was tested using exosomes already
purified from the aforementioned cell lines, obtaining LODs of
32, 73 and 203  103 exosomes per mL for SKBR3, T84 and
LNCaP, respectively. The biosensor was also used to detect
exosomes from patients suffering from breast, colorectal and
prostate cancer, matching in all cases their corresponding type
of exosomes.
Other groups have reported the possibility to detect EVs in a
non-specific way, that is, without adding Abs or aptamers to
recognize the EVs. For instance, Tian et al. reported the use of
SERS probes composed of gold nanostars and reporter mole-
cules, further modified with a bivalent cholesterol-labelled DNA
anchor (Fig. 9a and b).200 Target exosomes were captured using
magnetic beads functionalized with anti CD9 Abs. The captured
exosomes were then labelled with the SERS nanoprobes via
hydrophobic interactions between the cholesterol moieties and
the exosomal lipid membranes, resulting in a sandwich
complex. This complex could be magnetically captured and
Fig. 8 Comparison between the Raman technique and the SERS technique. The main difference lies in the enhanced Raman scattering from the
nanostructures used as substrates in SERS. Reproduced from ref. 197 with permission from The Royal Society of Chemistry.
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Fig. 9 Different SERS-based biosensors for the detection of exosomes. (a) Fabrication of SERS probes: Au nanostars containing reporter molecules
(4-MBA) and modified with a bivalent cholesterol-labelled DNA anchor. (b) SERS sensing strategy for exosome detection. Reproduced from ref. 200 with
permission from The Royal Society of Chemistry. (c) A schematic view of a PDA chip and Au@Ag@PDA SERS tag-based exosome sensors. Reproduced
from ref. 201 with permission from The Royal Society of Chemistry. (d) Schematic illustration of the experimental process of AgNCs on a specified high-
density hot-ring diameter area Au NR array substrate. (e) Field-emission scanning electron microscopy images of as-fabricated samples and (f) schematic
illustration of electromagnetic enhancement. Adapted from ref. 202 with permission from Elsevier.
























































































This journal is©The Royal Society of Chemistry 2020 J. Mater. Chem. B, 2020, 8, 6710--6738 | 6725
deposited on a silica slide for detection using a Raman spectro-
meter. Exosomes derived from HepG2 hepatocellular carcinoma
cells were used as a model for liver cancer diagnosis. A LOD of
27  103 exosomes per mL was reported, with a linear relation
between exosome concentration and corresponding SERS signal
ranging from 40 to 4  107 exosomes per mL. As a proof of
concept, serum samples from healthy and liver cancer patients
were tested. As already reported, the number of exosomes was
elevated in cancer patients, and the results were comparable
with those obtained using state-of-the-art technologies (purifica-
tion using the ExoEasy kit and quantification with qNano).
Meanwhile, Stremersch et al. used cationic AuNPs to ionically
adsorb exosome-like vesicles (ELVs), demonstrating the possibi-
lity to discriminate ELVs isolated from B16F10 melanoma cell
cultures and red blood cells (RBCs) with SERS.205 The same
group subsequently improved the system by applying an extra
silver layer in situ to remove interfering signals generated by the
AuNP coating.206 The Au@AgNPs core–shell system resulted in
SERS signals with improved signal-to-noise ratio, and conse-
quently, more vibrational modes could be identified. Further-
more, the improved system decreased the acquisition time by a
factor of 20. Lee et al. took advantage of a3b1 integrin over-
expression in exosomes derived from some cancerous cell lines
to detect exosomes isolated and purified from human ovarian
carcinoma cell lines (SKOV-3).207 In this case, SERS probes were
prepared using AgNPs functionalized with the LXY30 peptide,
able to selectively label the aforementioned integrin, and allowed
a specific detection of exosomes derived from SKOV-3 cells.
Recently, Pang et al. developed a smart system to test the
expression of programmed death-ligand 1 (PD-L1) on the exo-
some membrane using magnetite@TiO2 particles to capture the
exosomes.208 In recent years, several reports have revealed the
correlation of exosomal PD-L1 expression and anti-PD-L1/PD-1
therapy in order to treat tumours.209,210 The possibility to predict
if a patient will respond to anti-PD-L1/PD-1 therapy is of utmost
importance, considering the high price and side effects of
immune drugs. To study PD-L1 expression, exosomes purified
from A549 non-small cell lung cancer (NSCLC) cells and BEAS-2B
normal human bronchial epithelial cells were incubated with
magnetite@TiO2 particles to enrich and separate exosomes from
cell culture media or serum samples. No aptamers or Abs were
needed, as TiO2 can specifically interact with the phosphate
groups present on the lipid bilayer of exosomes.211 Once sepa-
rated, exosomes were labelled with the SERS tags, consisting
of Ag@Au@SERS reporter nanoprobes functionalized with anti
PD-L1 Abs. With this methodology exosomes containing PD-L1
were detected with a LOD of 1000 exosomes per mL. Interestingly,
the authors tested the possibility to detect the individual level of
exosomal PD-L1 in NSCLC patients at different stages, using
undiluted serum. Differences in exosomal PD-L1 expression could
be found among healthy patients and both early and late NSCLC
groups. Moreover, only 4 mL of serum sample and 40 minutes
were needed to complete the assay.
SERS biosensors can also be built by directly immobilizing
the EVs on a substrate before adding the SERS tag. For instance,
Li et al. created a SERS immunosensor for clinical pancreatic
cancer diagnosis using a polydopamine (PDA) polymerized
substrate to encapsulate Abs in order to capture exosomes
isolated from real samples or from culture media (Fig. 9c).201
Au@Ag@Raman reporter@PDA NPs modified with an Ab were
subsequently used as SERS tags. PDA substrates were used
to capture exosomes and Au@Ag@PDA SERS tags. Both the
substrate and the NPs were functionalized with diverse Abs to
detect common exosomal proteins (CD63 and CD9) or specific
pancreatic cancer-derived exosomal proteins (GPC1, EGFR,
EpCAM and Macrophage migration inhibitory factor). Impor-
tantly, this immunosensor was able to distinguish healthy from
pancreatic cancer patients, as well as metastatic from non-
metastatic tumors.
On the other side, efforts have been also devoted to enhance
the SERS signal by improving the SERS substrate. Kwizera et al.
combined SERS technology with a 3D printing methodology to
develop a chip platform functionalized with Abs to detect
exosomes.212 In this case, 35 nm AuNRs functionalized with a
Raman reporter were used as SERS tags. This platform had
microliter sample requirement and allowed the detection of
2 106 exosomes per mL from breast cancer cell lines in 2 hours.
Further, they showed that exosomes derived from different
cancer cells gave different protein profiles when compared to
exosomes derived from healthy cells. Other authors have devel-
oped a strong plasmonic gap-mode SERS substrate by assembling
silver nanocubes (AgNCs) on an AuNR pillar array surface, in
order to enhance the SERS signal (Fig. 9d–f).202 The Raman
reporter molecule was directly deposited on this substrate. Using
this approach, the possibility to distinguish exosomes derived
from lung normal and cancer cell lines was demonstrated.
Exosomes could be detected at concentrations 104–105 times
lower than that found in general blood samples (1011 exosomes
per mL) in a short time.
Remarkably, SERS can also serve as a valuable tool to
characterize subpopulations of exosomes from different origin
if combined with a multivariate method able to condense the
SERS data. For instance, Carmicheal et al. used principal
component and differential function analyses (PC-DFA) in
conjunction with SERS data in order to classify exosomes from
various cellular origins.213 Using this method, the authors were
able to differentiate serum-derived exosomes isolated from
healthy and pancreatic cancer patients with high sensitivity
and specificity. Meanwhile, Choi et al. used PCA to classify
SERS spectra (Fig. 10).214,215 By using this approach, NSCLC
derived exosomes were distinguished from normal alveolar cell-
derived exosomes with 95.3% sensitivity and 97.3% specificity.
Thereafter, the same group identified the unique SERS profiles
of NSCLC derived exosomes and correlated the unique peaks
with the Raman profiles of different exosomal protein markers
that could contribute to them (Fig. 10).215 In these approaches
exosomes were deposited onto a slide containing AuNPs.
Lastly, SERS-based biosensors have been also used for the
detection of microRNAs in EVs. In this context, exosomal
microRNAs have attracted attention in recent years due to their
significant role in regulating cancer progression.216 Pang et al.
proposed a one-step and one-pot assay for exosomal microRNA
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detection, based on a duplex-specific nuclease (DSN) assisted
SERS biosensor.217 To this end, Fe3O4@Ag-DNA NPs were used
to capture the exosomes and as SERS substrate, while Au@
Ag@SERS reporter structures were used as SERS tags. The
Fe3O4@Ag–Au@Ag SERS tag conjugates were formed through
the DNA linking between both types of structures. DNA probes
were specifically designed to recognize miRNA from plasma-
derived exosomes from pancreatic ductal adenocarcinoma
(PDAC) and chronic pancreatitis (CP) patients. The Raman
signal was induced by the ‘‘hot spots’’ between the Au@Ag of
SERS tag and the Ag shell of the Fe3O4@Ag substrate, especially
after magnetic isolation. When exosomal microRNA was pre-
sent, DNA could hybridize with it. DSN nuclease was added to
selectively cleave the DNA of the DNA/microRNA duplex, so that
the SERS tags could be separated from the Fe3O4@Ag substrate.
This induced SERS signal quenching which could be correlated
with the original concentration of microRNA. Using this tech-
nology, a detection limit of 1 aM (microRNA 10b) was achieved.
It was also reported that microRNA 10b levels were higher in
exosomes derived from PDAC patients when compared to those
derived from CP or normal patients. Similarly, Ma et al. proposed
the use of MNPs linked via DNA to Au@SERS reporter@AgAu
nanoparticles (SERS tags).218 DNA could specifically bind with
the complementary exosomal miRNA, while MNPs were used to
separate exosomes from serum and plasma media. Once again
miRNA/DNA duplexes could be specifically cleaved by DSN,
releasing SERS tags while miRNA was involved in other rounds
of signal amplification. This technique could detect a concen-
tration of 5 fM of miRNA21.
3.2.6. Surface plasmon resonance. SPR is a label-free tech-
nology that has been used to detect in real time the binding of
biomolecules onto a metal surface.219 Planar metal surfaces
composed of for instance gold or silver or nanostructured
surfaces can be used to fabricate these biosensors. The receptor
molecules such as Abs or aptamers are generally immobilized
on these surfaces; the subsequent binding of an EV will cause
changes in the local refractive index that will affect the optical
properties of the SP modes, and can be detected. Therefore,
SPR platforms are a label-free and powerful tool to detect and
quantify EVs. The presence of AuNPs can enhance the sensitiv-
ity by electronic coupling interaction of their LSPR and the SP
wave associated with the metal surface.185 Currently, however,
the great majority of examples to detect EVs do not include NPs,
but only surfaces.8,9
A remarkable example of a SPR-based platform was reported
by Im et al.79 The nano-plasmonic exosome (nPLEX) sensor
comprised arrays of periodic nanoholes patterned in a gold
film. Nanoholes were designed for matching their dimensions
(o200 nm) to exosome size, enhancing the detection sensitivity.
Three-dimensional simulation studies were performed to optimize
the geometry of the nanoholes, finding enhanced electromagnetic
fields tightly confined within the exosome size range. A multi-
channel multifluidics system was integrated to perform high-
throughput analyses. The surface was passivated using PEG, and
anti CD63 Abs were functionalized onto PEG chains. As a proof of
concept, exosomes isolated from a human ovarian cancer cell line
(CaOV3) were tested. Upon binding of exosomes, a change in
the local refractive index took place, shifting the spectral peaks.
The magnitude of spectral shift correlated with the molecular
mass density covering the sensor surface and thus enabled
quantitative analysis of EV proteins. The LOD was B3000
exosomes, 102-fold higher than that of an ELISA performed
using the same exosomes. Importantly, the signal could be
significantly increased by using AuNPs as secondary labels.
10 nm spherical AuNPs showed a 20% increase, while the signal
could be enhanced by 300% when using 50 nm Au nanostars.
Subsequently, the platform was functionalized with Abs against
various exosomal targets and tested using samples from ovarian
cancer patients and healthy patients as controls. It was found
that the levels of EpCAM and CD24 were elevated in the ovarian
cancer patient samples. An intrinsic diagnosis accuracy of
97% was reported, although a larger cohort of patients should
be used to validate the platform. Importantly, the whole analysis
could be accomplished in less than 30 min, and ascites samples
from patients were used with minimal processing, as they were
only membrane filtered to remove cells and debris.
3.2.7. Micronuclear magnetic resonance. Using MNPs and
magnetic resonance, Shao et al. developed a miniaturized
micronuclear magnetic resonance (mNMR) biosensor enabling
Fig. 10 Detection of unique Raman scattering profiles of lung cancer
cell-derived exosomes and comparison to the profiles of their potential
surface protein markers. Cancerous exosome-specific protein markers are
associated in terms of signal similarity. Reprinted with permission from
ref. 215. Copyright (2018) American Chemical Society.
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detection and protein profiling of exosomes.80 Importantly, this
sensing technique employs NMR magnetic fields, which can
penetrate even turbid samples. Thus, assays can be done in
complex samples such as blood with minimal interference.220
Click chemistry was used to label the exosomes with the
MNPs.80 The microfluidic platform also included a membrane
where these targeted exosomes were concentrated, and a micro-
coil for NMR detection. Placed in the NMR system, the presence
of MNPs caused a change in the transverse relaxation time of
the surrounding water molecules. As the signal change is
proportional to the concentration of MNPs, CD63-targeted
exosomes could be detected with a LOD of 104 exosomes.
Interestingly, it was possible to profile and differentiate exo-
somes in blood samples of patients with glioblastoma multi-
forme from healthy controls. Although the results were really
promising, adapting NMR to exosome detection presented
many engineering challenges.7 The same authors have also
reported different integrated platforms using MNPs to capture
the exosomes. Subsequently, quantitative polymerase chain
reaction or an electrochemical assay was used to detect mRNA
or to profile exosomes, respectively.221,222
4. Conclusions
In recent years, much effort has been put into the development
of POC devices for the isolation and analysis of EVs.223 For
instance, the Exochip and Exosearch are smart microfluidic
platforms able to capture and quantify EVs, using external
fluorometers.224,225 Going a step forward, other groups have
developed microfluidic devices where the detection system is
also included,222,226 or have demonstrated the possibility to
detect EVs using smartphones.227,228 The combination of these
platforms with NPs could enhance their performance, speeding
up the translation of EVs into clinical settings. Indeed, NPs
offer many advantages when compared to bulk materials, such
as unique optical properties or a high surface area that can be
exploited to design innovative biosensors. Among the different
sensing methodologies that can be used to detect EVs, each
technique has inherent advantages and drawbacks that need to
be taken into account (Table 4). For instance, LFIA tests are easy
to use and do not require sophisticated equipment, but their
sensitivity is lower than that reported using more complex
methodologies. Similarly, colorimetric biosensors using NPs
could be implemented as POC assays, as detection can be done
by the naked eye; however, an amplification method is routi-
nely needed to enhance the sensitivity, hampering in many
cases this portability. Electrochemical and fluorescence-based
biosensors are promising candidates for POC analysis as they
can be portable and sensitive at the same time,227,228 but the
use of NPs in these completely portable systems has not been
reported. Other methodologies such as SPR in combination
with NPs, while promising, have not been extensively explored
to date. For instance, although AuNPs have been shown to
increase the sensitivity of SPR platforms, their use is still
limited.79 Similarly, MNPs are widely used to separate EVs,
but their use to analyse them using RMN is limited because of
the small size of EVs.80
Currently, the majority of the devices reported to detect EVs
(Table 3) use Abs or aptamers to recognize them. Although the
chemistry to functionalize these biomolecules onto the NPs is
crucial, almost any work takes this point into account. As can
be seen in Table 3, these NP-based devices can provide higher
sensitivities than the ones obtained using standard techniques
for EV analyses, such as NTA (107–109 EVs per mL), flow
cytometry (107–109 EVs per mL), ELISA (109–1010 EVs per mL)
or WB (1011–1012 EVs per mL) (Table 2).79–81,229,230 Selecting the
appropriate chemistry to couple the biomolecule could further
enhance it.
Despite progressive advances in the field, the majority of the
devices where NPs are used to analyse EVs require their
previous isolation using traditional methods (Table 3). Meth-
odologies such as ultracentrifugation, density gradient centri-
fugation or size exclusion chromatography are generally time
consuming, should be performed by skilled personal and can
incur sample loss. On top of that, more than 1000 different
protocols to retrieve EVs from biological fluids have been
reported.236 Thus, without standard isolation procedures it is
difficult to establish detailed comparisons to evaluate the
performance of these detection platforms. These complications
are exacerbated by the fact that many reports lack minimal
information about the EVs, or important analytical information
of the device such as limit of quantification, precision, accuracy
or LOD. Even when the LOD is reported, as the units of
quantification differ between studies, it is difficult to establish
a real comparison. To overcome this issue, recommendations
for EV analysis and reporting can be followed.28,237
Lastly, the majority of the studies listed in Table 3 are at the
level of proof-of-concept, having being performed with EVs
isolated from cell lines. Although some of them included
patient samples, statistics should be improved by using large
patient cohorts. Advances in these fields will enable the accel-
eration of EVs incorporation into the clinic.
5. Future outlook
Nowadays the potential of EVs as a source of biomarkers is
widely accepted and we believe that liquid biopsies will open a
new avenue for early detection of cancer. Proof of this is the fact
that the first EV-based biopsies have started to reach the
market. One example is the ExoDx Prostate Test, a test based
on measurement of specific EV-RNA in urine by PCR that can
be used to predict high-grade prostate cancer.238 We expect that
during the next years additional tests will be generated for
other cancer types and diseases and that the first EV-protein
tests will be developed.
In the last few years, lab on a chip platforms have been
attracting more attention as they can improve portability,
efficiency, automation and miniaturization among others.
The combination of NPs with these platforms could enhance
their performance and speed up the translation of liquid
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biopsies into the clinic; however, there is still a long way to
reach this goal as the field faces several important challenges.
For instance, EV-based markers should be detectable with a few
and simple processing steps, preferentially directly in the cell-
free biofluid. Further technology advancements to specifically
detect tumor-derived subpopulations of EVs in a complex
mixture are also necessary, as human biofluids contain a
mixture of EVs released from diverse cell types. Lastly, high-
throughput EV separation along with high purity recovery and
device standardization should be also pursued.
In conclusion, although nanomaterials are playing a key role
in developing novel biosensors with enhanced sensitivity for
the detection of EVs, major efforts should be devoted to
enhance the portability and reproducibility of the devices to
be used in clinical settings. For future prospective, prototypes
where EVs isolation and analysis are integrated into the
same device are highly promising towards automated and
user-friendly POC devices. We also believe that orientation of
molecules on NPs could greatly improve the sensitivity, and
that by controlling the functionalization processes, many
platforms could enhance their performance. We expect that
in the next few decades, by addressing the aforementioned
challenges, the nanobiosensor field will result in the develop-
ment of easy platforms with the capacity to test clinical samples
with high selectivity and accuracy.
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Puebla and B. Auguié, et al., ACS Nano, 2020, 14, 28–117.
199 M. E. Stewart, C. R. Anderton, L. B. Thompson, J. Maria,
S. K. Gray, J. A. Rogers and R. G. Nuzzo, Chem. Rev., 2008,
108, 494–521.
200 Y.-F. Tian, C.-F. Ning, F. He, B.-C. Yin and B.-C. Ye, Analyst,
2018, 143, 4915–4922.
201 T.-D. Li, R. Zhang, H. Chen, Z.-P. Huang, X. Ye,
H. Wang, A.-M. Deng and J.-L. Kong, Chem. Sci., 2018, 9,
5372–5382.
202 K. Sivashanmugan, W.-L. Huang, C.-H. Lin, J.-D. Liao,
C.-C. Lin, W.-C. Su and T.-C. Wen, J. Taiwan Inst. Chem.
Eng., 2017, 80, 149–155.
203 S. Zong, L. Wang, C. Chen, J. Lu, D. Zhu, Y. Zhang, Z. Wang
and Y. Cui, Anal. Methods, 2016, 8, 5001–5008.
204 Z. Wang, S. Zong, Y. Wang, N. Li, L. Li, J. Lu, Z. Wang,
B. Chen and Y. Cui, Nanoscale, 2018, 10, 9053–9062.
205 S. Stremersch, M. Marro, B.-E. Pinchasik, P. Baatsen,
A. Hendrix, S. C. De Smedt, P. Loza-Alvarez, A. G.
Skirtach, K. Raemdonck and K. Braeckmans, Small, 2016,
12, 3292–3301.
206 J. C. Fraire, S. Stremersch, D. Bouckaert, T. Monteyne,
T. De Beer, P. Wuytens, R. De Rycke, A. G. Skirtach,
K. Raemdonck, S. De Smedt and K. Braeckmans, ACS Appl.
Mater. Interfaces, 2019, 11, 39424–39435.
207 C. Lee, R. Carney, K. Lam and J. W. Chan, J. Raman
Spectrosc., 2017, 48, 1771–1776.
208 Y. Pang, J. Shi, X. Yang, C. Wang, Z. Sun and R. Xiao,
Biosens. Bioelectron., 2020, 148, 111800.
209 G. Chen, A. C. Huang, W. Zhang, G. Zhang, M. Wu, W. Xu,
Z. Yu, J. Yang, B. Wang, H. Sun, H. Xia, Q. Man, W. Zhong,
L. F. Antelo, B. Wu, X. Xiong, X. Liu, L. Guan, T. Li, S. Liu,
R. Yang, Y. Lu, L. Dong, S. McGettigan, R. Somasundaram,
R. Radhakrishnan, G. Mills, Y. Lu, J. Kim, Y. H. Chen,
H. Dong, Y. Zhao, G. C. Karakousis, T. C. Mitchell,
L. M. Schuchter, M. Herlyn, E. J. Wherry, X. Xu and
W. Guo, Nature, 2018, 560, 382–386.
210 F. L. Ricklefs, Q. Alayo, H. Krenzlin, A. B. Mahmoud and
M. C. Speranza, et al., Sci. Adv., 2018, 4, eaar2766.
211 F. Gao, F. Jiao, C. Xia, Y. Zhao, W. Ying, Y. Xie, X. Guan,
M. Tao, Y. Zhang, W. Qin and X. Qian, Chem. Sci., 2019, 10,
1579–1588.
212 E. A. Kwizera, R. O’Connor, V. Vinduska, M. Williams, E. R.
Butch, S. E. Snyder, X. Chen and X. Huang, Theranostics,
2018, 8, 2722–2738.
213 J. Carmicheal, C. Hayashi, X. Huang, L. Liu, Y. Lu,
A. Krasnoslobodtsev, A. Lushnikov, P. G. Kshirsagar,
A. Patel, M. Jain, Y. L. Lyubchenko, Y. Lu, S. K. Batra and
S. Kaur, Nanomedicine, 2019, 16, 88–96.
214 J. Park, M. Hwang, B. Choi, H. Jeong, J. Jung, H. K. Kim,
S. Hong, J. Park and Y. Choi, Anal. Chem., 2017, 89,
6695–6701.
215 H. Shin, H. Jeong, J. Park, S. Hong and Y. Choi, ACS Sens.,
2018, 3, 2637–2643.
























































































6738 | J. Mater. Chem. B, 2020, 8, 6710--6738 This journal is©The Royal Society of Chemistry 2020
216 R. Bhome, F. Del Vecchio, G.-H. Lee, M. D. Bullock,
J. N. Primrose, A. E. Sayan and A. H. Mirnezami, Cancer
Lett., 2018, 420, 228–235.
217 Y. Pang, C. Wang, L. Lu, C. Wang, Z. Sun and R. Xiao,
Biosens. Bioelectron., 2019, 130, 204–213.
218 D. Ma, C. Huang, J. Zheng, J. Tang, J. Li, J. Yang and
R. Yang, Biosens. Bioelectron., 2018, 101, 167–173.
219 L. Grasso, R. Wyss, L. Weidenauer, A. Thampi,
D. Demurtas, M. Prudent, N. Lion and H. Vogel, Anal.
Bioanal. Chem., 2015, 407, 5425–5432.
220 Y. P. Chen, M. Q. Zou, C. Qi, M.-X. Xie, D.-N. Wang,
Y.-F. Wang, Q. Xue, J.-F. Li and Y. Chen, Biosens. Bioelectron.,
2013, 39, 112–117.
221 H. Shao, J. Chung, K. Lee, L. Balaj, C. Min, B. S. Carter,
F. H. Hochberg, X. O. Breakefield, H. Lee and
R. Weissleder, Nat. Commun., 2015, 6, 6999.
222 S. Jeong, J. Park, D. Pathania, C. M. Castro, R. Weissleder
and H. Lee, ACS Nano, 2016, 10, 1802–1809.
223 J. C. Contreras-Naranjo, H.-J. Wu and V. M. Ugaz, Lab Chip,
2017, 17, 3558–3577.
224 S. S. Kanwar, C. J. Dunlay, D. M. Simeone and S. Nagrath,
Lab Chip, 2014, 14, 1891–1900.
225 Z. Zhao, Y. Yang, Y. Zeng and M. He, Lab Chip, 2016, 16,
489–496.
226 J. Sierra, J. Marrugo-Ramı́rez, R. Rodriguez-Trujillo, M. Mir
and J. Samitier, Sensors, 2020, 20, 1317.
227 J. Ko, M. A. Hemphill, D. Gabrieli, L. Wu, V. Yelleswarapu,
G. Lawrence, W. Pennycooke, A. Singh, D. F. Meaney and
D. Issadore, Sci. Rep., 2016, 6, 31215.
228 L.-G. Liang, M.-Q. Kong, S. Zhou, Y.-F. Sheng, P. Wang,
T. Yu, F. Inci, W. P. Kuo, L.-J. Li, U. Demirci and S. Wang,
Sci. Rep., 2017, 7, 46224.
229 R. Xu, D. W. Greening, H.-J. Zhu, N. Takahashi and
R. J. Simpson, J. Clin. Invest., 2016, 126, 1152–1162.
230 F. A. W. Coumans, E. L. Gool and R. Nieuwland, Platelets,
2017, 28, 242–248.
231 Y. Liu, Q. Liu, S. Chen, F. Cheng, H. Wang and W. Peng,
Sci. Rep., 2015, 5, 12864.
232 S. L. Cobo, C. C. Silva, A. Moyano, M. O. Rodrı́guez, A. Paschen,
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